Maravai director receives 46,293 share award

LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

LUCIER GREGORY T reported acquisition or exercise transactions in this Form 4 filing.

Maravai LifeSciences Holdings director Gregory T. Lucier reported an amended Form 4 showing an equity award and updated holdings. He received 46,293 shares of Class A Common Stock in the form of restricted stock units granted on May 26, 2026 at a grant price of $0.00 per share, awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.

These restricted stock units vest in full on the earlier of one year from the grant date or the date of the 2027 annual meeting of stockholders. Following this award, Lucier directly owns 201,416 shares of Class A Common Stock and has an additional 109,784 shares held indirectly through a family partnership. The filing is also being amended to correct the purchase price previously reported on a Form 4 filed the same date.

Insider Trade Summary

Grant/Award: 46,293 shares

Grant/Award 2 txns

Insider LUCIER GREGORY T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	46,293	$0.00	$0.00
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 201,416 shares (Direct); Class A Common Stock — 109,784 shares (Indirect, By Family Partnership)

Footnotes (2)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
2. F2. This Form 4 is being amended to correct the purchase price previously reported on a Form 4 filed this date.

Key Figures

RSU grant size: 46,293 shares Grant price: $0.00 per share Direct holdings after award: 201,416 shares +2 more

5 metrics

RSU grant size 46,293 shares Restricted stock units granted on May 26, 2026

Grant price $0.00 per share Restricted stock unit award under 2020 Omnibus Incentive Plan

Direct holdings after award 201,416 shares Class A Common Stock directly owned after transactions

Indirect holdings via family partnership 109,784 shares Class A Common Stock held indirectly by family partnership

Vesting horizon Earlier of 1 year or 2027 meeting RSUs vest in full by earlier of one year from May 26, 2026 or 2027 annual meeting

Key Terms

restricted stock units, 2020 Omnibus Incentive Plan, annual meeting of stockholders, Form 4

4 terms

restricted stock units financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Omnibus Incentive Plan financial

"restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026"

annual meeting of stockholders financial

"vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders"

Form 4 regulatory

"This Form 4 is being amended to correct the purchase price previously reported on a Form 4 filed this date"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MRVI director Gregory T. Lucier report?

Gregory T. Lucier reported receiving an equity award of 46,293 restricted stock units of Maravai Class A Common Stock. The award was granted with a zero-dollar grant price under the company’s 2020 Omnibus Incentive Plan and is reflected in his updated share holdings.

How many MRVI shares does Gregory T. Lucier hold after this Form 4/A?

After this filing, Gregory T. Lucier directly holds 201,416 shares of Maravai Class A Common Stock. In addition, 109,784 shares are held indirectly through a family partnership, giving insight into both his direct and indirect equity exposure to the company.

What are the vesting terms of Lucier’s 46,293 restricted stock units in MRVI?

The 46,293 restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the date of Maravai’s 2027 annual meeting. This single-vesting schedule links the award to both time-based service and the company’s future shareholder meeting.

Why was this Maravai (MRVI) Form 4/A filed as an amendment?

The Form 4/A was filed to correct the purchase price previously reported on a Form 4 filed the same date. The amendment clarifies that the grant price for the 46,293 restricted stock units was $0.00 per share under the company’s equity incentive plan.

Is Gregory T. Lucier’s new MRVI award an open-market stock purchase?

No, the 46,293 shares represent a grant of restricted stock units, not an open-market purchase. The award was made under Maravai’s 2020 Omnibus Incentive Plan at a grant price of $0.00 per share as part of his compensation, subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 06:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUCIER GREGORY T

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIRCLE, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/28/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		A		46,293(1)	A	$0(2)	201,416	D
Class A Common Stock								109,784	I	By Family Partnership

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

2. This Form 4 is being amended to correct the purchase price previously reported on a Form 4 filed this date.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Gregory T. Lucier	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)